Glooko vs Hims & Hers
Side-by-side comparison of AI visibility scores, market position, and capabilities
Glooko is a digital health platform for diabetes and chronic condition management; syncs data from 250+ glucose meters, CGMs, insulin pumps, and wearables; supports remote patient monitoring for clinicians and health systems; raised $100M+;
About
Glooko is a digital health company founded in 2010 and headquartered in Palo Alto, California, that provides a comprehensive platform for diabetes and chronic condition management. The company's technology aggregates data from over 250 connected diabetes devices — including continuous glucose monitors (CGMs), blood glucose meters, insulin pumps, pens, and health wearables — into a single unified platform that serves both patients and their care teams. For patients, Glooko provides a mobile app offering personalized insights, trend analysis, and education based on their glucose, insulin, activity, and nutrition data. For healthcare providers and clinical teams, Glooko's Population Health platform enables remote patient monitoring — allowing endocrinologists, diabetes educators, and primary care physicians to track patient cohorts, identify high-risk individuals, and deliver data-driven care interventions at scale.
Consumer telehealth platform with Q3 2025 revenue of $599M (+49% YoY); 2.47M subscribers; 2025 guidance $2.3-2.4B; acquiring ZAVA for European expansion; GLP-1 weight loss, hair, and sexual health treatments shipped directly to subscribers.
About
Hims & Hers is a consumer telehealth and pharmacy platform founded in 2017 in San Francisco by Andrew Dudum, built on the mission of making high-quality healthcare affordable and stigma-free for conditions that people historically avoided treating due to embarrassment, cost, or access barriers. The platform's core technology combines a direct-to-consumer digital health interface with an integrated pharmacy network, enabling patients to complete asynchronous or synchronous consultations with licensed clinicians and receive prescription treatments — including compounded medications — delivered directly to their homes.\n\nHims & Hers serves patients across sexual health, hair loss, mental health, dermatology, and weight management. The company's expansion into GLP-1 compounded weight loss medications has been a significant growth catalyst, capitalizing on surging consumer demand for semaglutide and tirzepatide alternatives during periods of branded drug shortages. With 2.47 million subscribers and a subscription-centric business model, the platform generates predictable recurring revenue from patients on ongoing treatment protocols. The company's 2025 acquisition of ZAVA expands its addressable market into European telehealth markets.\n\nHims & Hers reported Q3 revenue of $599 million, a 49% year-over-year increase, and issued full-year 2025 guidance of $2.3 to $2.4 billion — a scale that makes it one of the largest consumer telehealth companies in the world. The company's ability to compound subscriber growth with expanding treatment categories and international expansion through ZAVA provides multiple vectors for continued revenue acceleration. As healthcare consumerization intensifies and patients increasingly manage chronic conditions through digital-first platforms, Hims & Hers' brand recognition, integrated pharmacy infrastructure, and subscription model give it a durable position in consumer health.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.